CLINICAL_TRIALS ClinicalTrials.gov record update

DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06620302
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:21.861900+00:00
Published At: 2026-02-24T00:00:00+00:00
Record Updated At: 2026-02-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Childhood Fibrolamellar Carcinoma", "Recurrent Childhood Fibrolamellar Carcinoma", "Recurrent Childhood Malignant Solid Neoplasm", "Recurrent Fibrolamellar Carcinoma", "Recurrent Malignant Solid Neoplasm", "Refractory Childhood Fibrolamellar Carcinoma", "Refractory Childhood Malignant Solid Neoplasm", "Refractory Fibrolamellar Carcinoma", "Refractory Malignant Solid Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-24"
protocolSection.identificationModule.nctId: "NCT06620302"
protocolSection.identificationModule.officialTitle: "DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.